sn-6

SN 6 (SN6) is a selective Na+ Ca2+ exchanger (NCX) inhibitor (IC50s of NCX1: 2.9 μM , NCX2: 16 μM ,NCX3: 8.6 μM)

CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1 2 ~20 hours)[1][2].

1-1(Z)-Octadecenyl-2-docosahexaenoyl-sn-glycero-3-PE (18:0p 22:6-PE) is a lipid identified in rat brain tissue using mass spectrometry imaging techniques. It exhibits specific structural and distribution properties, allowing the differentiation of isomers of various fatty acid chains through refined methods.

1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0-22:6 PE) is a lipid compound utilized in the preparation of liposomes. Liposomes, forming the central component of concentric phospholipid bilayer vesicles, are pivotal in constructing drug delivery systems for anti-cancer and anti-infection applications. They effectively encapsulate hydrophilic payloads within their aqueous internal spaces, while lipophilic compounds are integrated into and become part of the lipid bilayer. This compound is particularly effective for delivering antisense oligonucleotides, addressing challenges such as inefficient cellular uptake and rapid loss in the body.

1-Arachidonoyl lysophosphatidic acid is a phospholipid containing arachidonic acid at the sn-1 position. It has been found in rat brain as 37% of the arachidonic acid-containing lysophosphatidic acid (LPA) species and is a precursor to 1-arachidonoyl glycerol . 1-Arachidonoyl lysophosphatidic acid binds to the LPA2/EDG4 receptor with an EC50 value of approximately 10 nM. It prevents TNF-α and IL-6 secretion in wild-type but not Lpa2-/- dendritic cells stimulated by LPS. It also decreases differentiation of HT-29 human colon carcinoma cells to goblet cells in the presence of sodium butyrate.

1,2,3-Trioctanoyl-rac-glycerol-13C3 is intended for use as an internal standard for the quantification of 1,2,3-trioctanoyl-rac-glycerol by GC- or LC-MS. 1,2,3-Trioctanoyl-rac-glycerol is a triacylglycerol that contains octanoic acid at the sn-1, sn-2, and sn-3 positions. Dietary administration of 1,2,3-trioctanoyl-rac-glycerol increases hippocampal levels of the glycolytic metabolites glucose 6-phosphate, fructose 6-phosphate, and β-hydroxybutyrate and the seizure threshold in the 6 Hz psychomotor seizure test in mice.1 Formulations containing 1,2,3-trioctanoyl-rac-glycerol have been used in cosmetic products as thickening and skin-conditioning agents.

(R)-KT109 is the (R) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (R)-KT109 is an inhibitor of DAGLβ (IC50 = 0.79 nM) and of DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol . It also inhibits α/β-hydrolase domain-containing protein 6 (ABHD6) with an IC50 value of 2.51 nM. (R)-KT109 is more potent at DAGLβ, DAGLα, and ABHD6 than (S)-KT109 .

(S)-KT109 is the (S) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (S)-KT109 is a less potent inhibitor of DAGLβ (IC50 = 39.81 nM), DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM), and α/β-hydrolase domain-containing protein 6 (ABHD6; IC50 = 630.9 nM) than (R)-KT109 .

1-Stearoyl-2-docosahexaenoyl-sn-glycerol (18:0-22:6 DG) is a diacylglycerol capable of binding to RasGRP and modulating the activation of MAP kinases.

1,2,3-Tri-6(Z)-octadecenoyl glycerol, a triacylglycerol, incorporates 6(Z)-octadecenoic acid (cis-petroselinic acid) into the sn-1, sn-2, and sn-3 positions. This compound is prevalent in plant seed oils.

Irinotecan-d10 Hydrochloride is a deuterated compound of Irinotecan Hydrochloride. Irinotecan Hydrochloride has a CAS number of 100286-90-6. Irinotecan Hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.